Zinc transporter 8 autoantibody testing requires age-related cut-offs by Grace, SL et al.
BMJ Open Diab Res Care 2021;9:e002296. doi:10.1136/bmjdrc-2021-002296
Open access 
1
Zinc transporter 8 autoantibody testing 
requires age- related cut- offs
Sian Louise Grace   ,1 Angela Cooper,2 Angus G Jones,1,3 
Timothy James McDonald   1,2
1The Institute of Biomedical & 
Clinical Science, University of 
Exeter, Exeter, UK
2Academic Department of 
Clinical Biochemistry, Royal 
Devon and Exeter NHS 
Foundation Trust, Exeter, UK
3Macleod Diabetes and 
Endocrine Centre, Royal Devon 
and Exeter NHS Foundation 
Trust, Exeter, UK
Correspondence to
Professor Timothy James 
McDonald;  
 timothy. mcdonald@ nhs. net
To cite: Grace SL, Cooper A, 
Jones AG, et al. Zinc transporter 
8 autoantibody testing 
requires age- related cut- offs. 
BMJ Open Diab Res Care 
2021;9:e002296. doi:10.1136/
bmjdrc-2021-002296
 ► Additional supplemental 
material is published online 
only. To view, please visit the 
journal online (http:// dx. doi. 
org/ 10. 1136/ bmjdrc- 2021- 
002296).
Received 31 March 2021
Accepted 17 July 2021
Original research
Immunology and transplantation
© Author(s) (or their 
employer(s)) 2021. Re- use 
permitted under CC BY- NC. No 
commercial re- use. See rights 
and permissions. Published 
by BMJ.
ABSTRACT
Introduction Zinc transporter 8 autoantibodies (ZnT8A) 
are biomarkers of beta cell autoimmunity in type 1 
diabetes that have become more widely available to 
clinicians in recent years. Robust control population- 
defined thresholds are essential to ensure high clinical 
specificity in islet autoantibody testing. We aimed to 
determine the optimal cut- offs for ZnT8A testing.
Research design and methods 97.5th and 99th centile 
cut- offs were determined using residual clinical sera 
from 1559 controls aged between 0 and 83 years with no 
history of diabetes and a hemoglobin A1c level of less than 
6.0% (<42 mmol/mol). ZnT8A were measured by ELISA 
(RSR, Cardiff, UK) on a Dynex DS2 ELISA robot (Dynex, 
Preston, UK). We assessed the impact of age- related cut- 
offs in comparison with the manufacturer’s recommended 
threshold in a mixed cohort of young- onset (<age 30) 
diabetes (UNITED study (Using pharmacogeNetics to 
Improve Treatment in Early- onset Diabetes), n=145).
Results Using the manufacturer’s limit of detection, 6 
WHO U/mL, 16.2% of people in the control cohort had 
detectable levels of ZnT8A and those who had detectable 
ZnT8A were much more likely to be younger (p<0.0001). 
The 97.5th and 99th centile thresholds were substantially 
higher in younger participants: 18 and 127 WHO U/mL 
(tested under 30 years) in comparison with 9 and 21 
WHO U/mL (tested 30 years and over). In the UNITED 
cohort some of those found to be ZnT8A- positive by 
the manufacturer’s threshold but negative using the 
appropriate 99% centile cut- off (127 WHO U/mL) displayed 
characteristics suggestive of type 2 diabetes.
Conclusions Age- related thresholds are needed 
for ZnT8A testing. In those aged <30 years, use of 
manufacturers’ recommended cut- offs may result in low 
test specificity and potentially high rates of false positive 
test results in patients who do not have autoimmune 
diabetes.
INTRODUCTION
Islet autoantibodies, including glutamate 
decarboxylase (GADA), islet antigen-2 (IA- 
2A) and insulin, have traditionally been used 
as biomarkers of the autoimmune attack 
occurring in type 1 diabetes (T1D). The pres-
ence of islet autoantibodies is useful in differ-
entiating T1D from other forms of diabetes 
and is used in research to stratify the risk of 
progression to T1D in cohort studies.1 2 Zinc 
transporter 8 autoantibodies (ZnT8A) are 
the most recently characterized islet autoan-
tibody target of T1D autoimmunity, found in 
66%–80% of Caucasian patients at diagnosis 
and detectable in approximately 26% of indi-
viduals with T1D previously categorized as 
autoantibody- negative.3 In those diagnosed 
young, ZnT8A have been found to be associ-
ated with a more acute onset of disease and a 
greater probability of ketoacidosis at presen-
tation.4 ZnT8A have also been found to help 
exclude maturity onset diabetes of the young 
(MODY), identifying an additional 18% of 
probable T1D (in comparison with GADA 
and IA- 2A autoantibodies alone) in indi-
viduals with significant endogenous insulin 
secretion.5 ZnT8A testing has become widely 
available in clinical practice.
The interpretation of islet autoantibodies 
requires robust and well- defined cut- offs to 
ensure high clinical specificity. Islet auto-
antibodies are found on a continuum of 
Significance of this study
What is already known about this subject?
 ► Zinc transporter 8 autoantibodies (ZnT8A) are in-
creasingly used in clinical practice for classification 
of diabetes and for prediction of type 1 diabetes in a 
research setting.
 ► Thresholds of positivity have not yet been robustly 
defined and the impact of age on thresholds has not 
been examined.
What are the new findings?
 ► Healthy controls, with no history of diabetes and 
aged under 30 years, are more likely to have higher 
levels of detectable ZnT8A.
 ► The 97.5th and 99th centile cut- offs were signifi-
cantly higher in those tested under 30 years in com-
parison with those tested over 30 years.
How might these results change the focus of 
research or clinical practice?
 ► Clinical laboratories need to establish robust age- 
specific thresholds for ZnT8A testing, as without 
these, false positive results are likely to be common 
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concentration and are often detectable at low levels in 
the population without diabetes.6 7 Therefore, islet auto-
antibody cut- offs are normally based on centiles of a 
control population. Usually, the 97.5th or 99th centile of 
a population without diabetes is used as a positive cut- 
off (specificity 97.5% or 99%), depending on the spec-
ificity required for the clinical scenario.8–10 However, 
testing of sufficient numbers of controls without diabetes 
to accurately determine test threshold is expensive, and 
in practice the use of the limit of detection (LOD), or 
manufacturers’ recommended cut- off, is common.11 The 
impact of age on optimal thresholds of ZnT8A positivity 
has not yet been assessed.
We aimed to define robust thresholds of positivity for 
ZnT8A testing in a European population using the RSR 
ZnT8A ELISA assay and assess whether these are affected 




To establish an antibody titer cut- off for ZnT8A and 
assess the impact of age, residual sera from 1559 routine 
clinical samples of patients aged between 0 and 83 years 
of age without a clinical history of diabetes and a hemo-
globin A1c level of less than 6.0% (<42 mmol/mol) were 
analyzed at the Academic Department of Blood Sciences, 
Royal Devon and Exeter Hospital (Exeter, UK).
Assessment of threshold validity
Threshold validity and the effects of age- related cut- offs 
were assessed on 145 patients with young- onset diabetes 
(111 diagnosed with T1D, 31 with type 2 diabetes and 
3 with another diabetes type). Patients were identified 
from the UNITED (Using pharmacogeNetics to Improve 
Treatment in Early- onset Diabetes) cohort,12 an unse-
lected cross- sectional cohort of participants diagnosed 
with diabetes less than 30 years, but recruited before the 
age of 50 years. All included participants had been tested 
for ZnT8A (online supplemental table 1).
ZnT8A analysis
ZnT8A were analyzed using an ELISA commercial 
kit (RSR, Cardiff, UK) on a Dynex DS2 ELISA robot 
(Dynex, Preston, UK). The RSR ZnT8A ELISA is capable 
of detecting and quantifying autoantibodies specific to 
R325 or to W325 polymorphic variants of ZnT8A. This 
laboratory participates in the islet autoantibody stan-
dardization program (IASP), an external blinded quality 
assurance program for islet autoantibodies.13 The assay 
LOD is 6 U/mL and the manufacturer’s recommended 
cut- off for positivity  ≥15 U/mL.
Data analysis
The 5- year rolling average percentage with detectable 
ZnT8A and ZnT8A median titer were plotted (figure 1). 
The cut- offs were defined by using the 97.5th and 99th 
centiles. The specificity of the manufacturer’s LOD was 
assessed by applying it to the overall control cohort, 
conducting a subanalysis of each age group (less than 
30 years and 30 years and over) and evaluating by the 
proportion positive. Fisher’s exact test was used to 
compare groups above and below the LOD.
To assess the validity of the newly defined age- related 
cut- offs, the 99th centile cut- offs were applied to reduce 
the potential misclassification of patients with MODY, 
retrospectively to the UNITED cohort.5 In those tested 
under 30, we assessed the characteristics of participants 
who were positive for ZnT8A using the manufactur-
er’s recommended cut- off (15 U/mL) but negative for 
ZnT8A using an appropriate (99th centile) cut- off based 
from the control population of comparable age.
All statistical analyses were carried out using Stata/SE 
V.16.0, and figure 2 was drawn with GraphPad Prism Soft-
ware V.8.
RESULTS
Detectable ZnT8A levels in the control population are common 
in those aged under 30 years
Using the manufacturer’s reported LOD, 6 U/mL, 16.2% 
(95% CI 0.14 to 0.18) of participants in the control 
cohort had detectable ZnT8A. The 5- year rolling average 
of % detectable was plotted, and a marked decline in % 
detectable in early adulthood with stable low levels of 
detectable ZnT8A after age 30 was observed (figure 1). 
Therefore we split the control cohort into those tested 
under and over 30 years. The prevalence of detectable 
ZnT8A was strongly related to age: in those aged under 
30 years, 21% (n=229, 79% specificity, 95% CI 0.19 to 
0.24) had detectable ZnT8A; in contrast only 5% (n=24, 
95% specificity, 95% CI 0.03 to 0.07) of those tested 30 
years and over were over the LOD (p<0.0001).
Appropriate cut-offs for ZnT8A testing widely vary by age
For those tested under 30 years, the 97.5th and 99th 
centile cut- offs were 18 U/mL and 127 U/mL, respec-
tively. However, for those tested aged 30 years and 
over, the 97.5th and 99th centile cut- offs were 9 U/mL 
and 21 U/mL (figure 2). Therefore, to maintain assay 
Figure 1 Line graph of the 5- year rolling average of the 
percentage of those with detectable ZnT8A. The rolling 
average shows a drop to consistently <10% with detectable 
ZnT8A after the age of 30 years. LOD ≥6 U/mL. LOD, limit of 
detection; ZnT8A, zinc transporter 8 autoantibodies.
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specificity, those tested under the age of 30 years would 
need a higher cut- off in comparison with those tested 
aged 30 and over.
Age-related cut-offs for ZnT8A testing reclassify patients as 
negative who have a more type 2 diabetic phenotype
When the age- related 99th centile cut- offs of 127 U/
mL and 21 U/mL (increased from the manufacturer’s 
cut- off, 15 U/mL) were applied to the UNITED cohort 
retrospectively, 23 participants tested under 30 years 
were reclassified as ZnT8A- negative. Of these eight 
were now classified as autoantibody- negative and some 
exhibited a more type 2 diabetic phenotype (table 1). 
Three of eight were non- insulin- treated, and three of 
five had high urinary C peptide to creatinine ratio levels 
(≥0.6 nmol/L). Moreover, four of the patients were over-
weight ( ≥25) and three were obese ( ≥30). In contrast, in 
those who remained positive for ZnT8A, above the 99th 
centile age- related cut- off, 85% were positive for one or 
more additional islet autoantibodies (GADA or IA- 2A) 
and all those who were single ZnT8A positive above the 
99th centile were on insulin treatment.
Age-specific thresholds for ZnT8A in the IASP increased 
specificity without loss of sensitivity
When the 99th centile age- specific cut- offs described 
here were applied to a separate set of control samples 
(n=140) as part of the IASP 2020 workshop, specificity 
was high (98.9%), without loss of sensitivity (74.0%). This 
is in comparison with a specificity of 97% and a sensitivity 
of 74% reported in the assay insert by the manufacturer 
when their ≥15 U/mL cut- off was used.14
DISCUSSION
This study has shown that detectable ZnT8A levels above 
the manufacturer’s LOD are very common in a control 
population without diabetes, occurring in 21% of those 
tested under the age of 30 years and in 5% of those tested 
aged 30 and over. Where ZnT8A are detectable, titers are 
higher in younger individuals. Therefore using the same 
cut- off to define ZnT8A positivity for all ages could result 
in lower test specificity in young patients and poten-
tially high rates of false positive test results. In our unse-
lected population with young- onset diabetes, some of the 
participants with positive ZnT8A above the manufactur-
er’s recommended cut- off but ZnT8A- negative using an 
Figure 2 Plot of ZnT8A titers in healthy controls (n=1559). 
Dotted lines indicate the 97.5th and 99th percentiles for <30 
years (purple; n=1078) and ≥30 years (red; n=481). Black 
dotted line indicates the LOD (6 U/mL). Black solid lines 
indicate the median ZnT8A titer. LOD, limit of detection; 
ZnT8A, zinc transporter 8 autoantibodies.



























1 10–15 3.8 Insulin 28.3 48 (6.5) 0.79 3.8 56.6 4.2
2 10–15 14.8 Insulin 24.5 48 (6.5) 0.29 14.8 54.1 15.1
3 15–20 0.2 Insulin 46.7 107 (11.9) 2.02 0.2 52.4 0.1
4 15–20 5.9 Insulin 21.0 86 (10) 0.21 5.9 35.9 6.0
5 25–30 1.0 Tablet 47.5 53 (7) – – 32.7 1.0
6 20–25 1.2 Insulin 22.0 43 (6.1) 0.98 3.0 26.6 3.1
7 25–30 0.9 Tablet – 40 (5.8) – – 24.9 1.0
8 25–30 0.2 Tablet 32.5 115 (12.7) – – 17.2 0.0
Inclusion criteria were now negative for ZnT8A with new 99th centile cut- off and negative for glutamate decarboxylase and islet antigen-2 
autoantibodies.
– indicates missing data.
For UCPCR, a result ≥0.6 indicates substantial endogenous insulin secretion.
ZnT8A titer: level of units of ZnT8A present in the serum.
*For reasons of patient anonymity.
†At latest follow- up.
BMI, body mass index; HbA1c, hemoglobin A1c; UCPCR, urinary C peptide to creatinine ratio; UNITED, Using pharmacogeNetics to Improve 
Treatment in Early- onset Diabetes; ZnT8A, zinc transporter 8 autoantibodies.
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appropriate population- based (99th centile) threshold 
had the clinical characteristics of type 2 diabetes.
The 99th age- specific cut- offs improved performance 
of this assay in IASP, increasing specificity without loss of 
sensitivity (98.9% and 74.0%, respectively). The average 
specificity and sensitivity were 94.4% and 64.1% for this 
assay across the other laboratories submitting results,15 
therefore increasing confidence in the use of age- 
restricted thresholds for this assay.
The mechanisms that result in increased background 
prevalence and titer of ZnT8A in the young healthy 
control cohort are unknown. In healthy people we may 
speculate that it could be due to differences in immune 
system maturity or cross- reactivity to an infection mode 
commonly seen in the young, for example, cross- 
reactivity between ZnT8A and an antigen expressed by 
Mycobacterium avium subspecies paratuberculosis, which 
has been described.16 Another possibility for the higher 
titer and prevalence of ZnT8A in those tested <30 years in 
the control cohort is that there is a potential enrichment 
of individuals in the prodrome stage of T1D. However, 
the overall life prevalence of T1D is less than 0.3% (with 
approximately half of cases occurring after age 30)17 and 
therefore will be contributing only a very small amount to 
the difference between <30 and >30 cohorts (~0.15%). To 
our knowledge, this is one of the first studies to show age 
effects of ZnT8A on thresholds of positivity. A previous 
study by Vermeulen et al7 reported using age- restricted 
cut- offs for positivity for their liquid- phase radiobinding 
assay to detect ZnT8A. Their age cut- offs differed from 
ours (0–14 years and 15–39 years) and their control 
population was considerably smaller (n=761), with only 
those aged up to 39 assessed.
Due to the nature of the control cohort, the findings 
of this study are limited to one population which is 
predominantly of European descent. In addition, this 
study only used one assay type for ZnT8A; however, the 
RSR ELISA is used by many clinical laboratories since it 
was distributed and validated in 2013.18–20 Differences 
in ZnT8A prevalence have been reported in non- white 
ethnic patients with diabetes; defining appropriate refer-
ence ranges for different ethnicities and for other assays 
will be important areas for future research.21 22 A further 
limitation is that although this is a large cohort, far in 
excess of what has been previously reported,9 19 23 the 
sample size is still insufficient to do more than visually 
assess an optimal age cut- off. Therefore, an even larger 
sample size would be needed to give greater detail on 
optimal test cut- offs for different age groups.
High clinical specificity of islet autoantibody tests is of 
particular importance in the setting of low prior preva-
lence, such as the case of prediction of T1D in the general 
population or the diagnosis of autoimmune diabetes in 
older adults.17 By setting robust and well- defined cut- 
offs for each assay based on appropriate control popu-
lations, this will ensure high assay specificity and reduce 
potentially high rates of false positives in those with non- 
autoimmune diabetes. This is of increasing importance 
for studies into the prediction of T1D due to the recent 
progressions in intervention therapy research24 and 
in differentiating autoimmune from other forms of 
diabetes.25 We have shown potential misclassification of 
diabetes types due to the use of manufacturers’ recom-
mended cut- off. This is likely to affect previous work 
where reported prevalence of ZnT8A has varied and 
manufacturers’ guidelines of cut- offs have been used 
instead of a robust population- defined threshold.
CONCLUSION
In those aged <30 years, a higher age- related threshold 
is likely to be needed for ZnT8A testing to prevent 
low test specificity and potentially high rates of false 
positive test results in patients who do not have auto-
immune diabetes.
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